Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 108 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $277,000 | -40.9% | 8,204 | -32.8% | 0.00% | -66.7% |
Q3 2020 | $469,000 | +359.8% | 12,207 | +211.1% | 0.00% | +200.0% |
Q1 2020 | $102,000 | +168.4% | 3,924 | +166.9% | 0.00% | – |
Q1 2019 | $38,000 | -95.2% | 1,470 | -96.2% | 0.00% | -100.0% |
Q4 2018 | $797,000 | – | 39,183 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |